Cargando…

Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease

INTRODUCTION: Synaptic dysfunction and degeneration is one of the earliest events in Alzheimer's disease (AD) and the best correlate of cognitive decline. Thus, identification and validation of biomarkers reflecting synaptic degeneration to be used as prognostic biomarkers are greatly needed. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nilsson, Johanna, Gobom, Johan, Sjödin, Simon, Brinkmalm, Gunnar, Ashton, Nicholas J., Svensson, Johan, Johansson, Per, Portelius, Erik, Zetterberg, Henrik, Blennow, Kaj, Brinkmalm, Ann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Cerebrospinal Fluid Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8087978/ https://www.ncbi.nlm.nih.gov/pubmed/33969172 http://dx.doi.org/10.1002/dad2.12179

Ejemplares similares

The relationship between cerebrospinal fluid tau markers, hippocampal volume, and delayed primacy performance in cognitively intact elderly individuals
por: Bruno, Davide, et al.
Publicado: (2015)

Cerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease
por: Dhiman, Kunal, et al.
Publicado: (2020)

Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition
por: Wesenhagen, Kirsten E.J., et al.
Publicado: (2022)

Measurement batch differences and between‐batch conversion of Alzheimer's disease cerebrospinal fluid biomarker values
por: Ma, Yue, et al.
Publicado: (2021)

Pre‐analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF
por: Hansson, Oskar, et al.
Publicado: (2020)

CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status
por: Dong, Ruocheng, et al.
Publicado: (2021)

Sex differences in CSF biomarkers for neurodegeneration and blood‐brain barrier integrity
por: Skillbäck, Tobias, et al.
Publicado: (2021)

Periodontal dysbiosis associates with reduced CSF Aβ42 in cognitively normal elderly
por: Kamer, Angela R., et al.
Publicado: (2021)

A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease
por: Edwin, Trine Holt, et al.
Publicado: (2020)

Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?
por: Del Campo Milan, Marta, et al.
Publicado: (2015)

Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease
por: Lourenco, Mychael V., et al.
Publicado: (2020)

A study of the longitudinal changes in multiple cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers on converter and non‐converter Alzheimer's disease subjects with consideration for their amyloid beta status
por: Morar, Ulyana, et al.
Publicado: (2022)

Higher cerebrospinal fluid tau is associated with history of traumatic brain injury and reduced processing speed in Vietnam‐era veterans: A Department of Defense Alzheimer's Disease Neuroimaging Initiative (DOD‐ADNI) study
por: Clark, Alexandra L., et al.
Publicado: (2021)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020)

Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)

Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA): Cerebrovascular disease and the failure of elimination of Amyloid‐β from the brain and retina with age and Alzheimer's disease‐Opportunities for Therapy
por: Carare, Roxana O., et al.
Publicado: (2020)

Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD
por: Hajjar, Ihab, et al.
Publicado: (2020)

The effect of lumbar puncture on the neurodegeneration biomarker neurofilament light in macaque monkeys
por: Boehnke, Susan E., et al.
Publicado: (2020)

An automated clinical mass spectrometric method for identification and quantification of variant and wild‐type amyloid‐β 1‐40 and 1‐42 peptides in CSF
por: DeMarco, Mari L., et al.
Publicado: (2020)

Depressive symptoms and CSF Alzheimer's disease biomarkers in relation to clinical symptom onset of mild cognitive impairment
por: Chan, Carol K., et al.
Publicado: (2020)

Deciphering the factors that influence participation in studies requiring serial lumbar punctures
por: Day, Gregory S., et al.
Publicado: (2020)

Association of cognitive impairment severity with potentially avoidable readmissions: A retrospective cohort study of 8897 older patients
por: Mitsutake, Seigo, et al.
Publicado: (2021)

Diagnostic and prognostic performance of CSF α‐synuclein in prion disease in the context of rapidly progressive dementia
por: Mastrangelo, Andrea, et al.
Publicado: (2021)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Interaction of CSF α‐synuclein and amyloid beta in cognition and cortical atrophy
por: Lee, Young‐gun, et al.
Publicado: (2021)

Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
por: van den Berg, Emma, et al.
Publicado: (2023)

Intraventricular recombinant alpha-interferon in subacute sclerosing panencephalitis
por: Cianchetti, C., et al.
Publicado: (1991)

Fluid Biomarkers for Synaptic Dysfunction and Loss
por: Camporesi, Elena, et al.
Publicado: (2020)

Targeting LAMP2 in human cerebrospinal fluid with a combination of immunopurification and high resolution parallel reaction monitoring mass spectrometry
por: Sjödin, Simon, et al.
Publicado: (2016)

Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders
por: Sjödin, Simon, et al.
Publicado: (2017)

Cerebrospinal fluid physiology: visualization of cerebrospinal fluid dynamics using the magnetic resonance imaging Time-Spatial Inversion Pulse method
por: Yamada, Shinya
Publicado: (2014)

The embryonic blood-cerebrospinal fluid barrier function before the formation of the fetal choroid plexus: role in cerebrospinal fluid formation and homeostasis
por: Bueno, David, et al.
Publicado: (2014)

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
por: Babić, Mirjana, et al.
Publicado: (2014)

Embryonic cerebrospinal fluid in brain development: neural progenitor control
por: Gato, Angel, et al.
Publicado: (2014)

A computational model of cerebrospinal fluid production and reabsorption driven by Starling forces
por: Buishas, Joel, et al.
Publicado: (2014)

Measurement of cerebrospinal fluid formation and absorption by ventriculo-cisternal perfusion: what is really measured?
por: Orešković, Darko, et al.
Publicado: (2014)

Higher baseline levels of CSF inflammation increase risk of incident mild cognitive impairment and Alzheimer's disease dementia
por: Contreras, Joey A., et al.
Publicado: (2022)

Plasma biomarkers predict cognitive trajectories in an ethnoracially and clinically diverse cohort: Mediation with hippocampal volume
por: Sapkota, Shraddha, et al.
Publicado: (2022)

Hepatic and renal function impact concentrations of plasma biomarkers of neuropathology
por: Berry, Kacey, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d09fa6ehbr713ucda4d1h7adfp